152 related articles for article (PubMed ID: 6429046)
1. Preparation and characterization of a nontoxic polysaccharide-protein conjugate that induces active immunity and passively protective antibody against Pseudomonas aeruginosa immunotype 1 in mice.
Tsay GC; Collins MS
Infect Immun; 1984 Jul; 45(1):217-21. PubMed ID: 6429046
[TBL] [Abstract][Full Text] [Related]
2. O-polysaccharide-protein conjugates induce high levels of specific antibodies to Pseudomonas aeruginosa immunotype 3 lipopolysaccharide.
van de Wiel PA; Witvliet MH; Evenberg D; Derks HJ; Beuvery EC
Vaccine; 1987 Mar; 5(1):33-8. PubMed ID: 2437718
[TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Furer E; Sadoff JC; Germanier R
Infect Immun; 1986 Apr; 52(1):161-5. PubMed ID: 3082756
[TBL] [Abstract][Full Text] [Related]
4. High-molecular-weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2.
Pier GB; Sidberry HF; Sadoff JC
Infect Immun; 1981 Nov; 34(2):461-8. PubMed ID: 6171520
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.
Cryz SJ; Fürer E; Cross AS; Wegmann A; Germanier R; Sadoff JC
J Clin Invest; 1987 Jul; 80(1):51-6. PubMed ID: 3110215
[TBL] [Abstract][Full Text] [Related]
6. Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa.
Pier GB; Sidberry HF; Sadoff JC
Infect Immun; 1978 Dec; 22(3):919-25. PubMed ID: 103841
[TBL] [Abstract][Full Text] [Related]
7. Immunochemical characterization of high-molecular-weight polysaccharide from Fisher immunotype 3 Pseudomonas aeruginosa.
Pier GB; Pollack M; Cohen M
Infect Immun; 1984 Aug; 45(2):309-13. PubMed ID: 6430805
[TBL] [Abstract][Full Text] [Related]
8. Active and passive immunity against Pseudomonas aeruginosa with a ribosomal vaccine and antiserum in C3H/HeJ mice.
Lieberman MM; Ayala E
J Immunol; 1983 Jul; 131(1):1-3. PubMed ID: 6408166
[No Abstract] [Full Text] [Related]
9. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa.
Mates A; Zand P
J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979
[TBL] [Abstract][Full Text] [Related]
10. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB
J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
Cryz SJ; Sadoff JC; Fürer E; Germanier R
J Infect Dis; 1986 Oct; 154(4):682-8. PubMed ID: 3091708
[TBL] [Abstract][Full Text] [Related]
12. Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide.
Stoll BJ; Pollack M; Young LS; Koles N; Gascon R; Pier GB
Infect Immun; 1986 Sep; 53(3):656-62. PubMed ID: 2427453
[TBL] [Abstract][Full Text] [Related]
13. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.
Hemachandra S; Kamboj K; Copfer J; Pier G; Green LL; Schreiber JR
Infect Immun; 2001 Apr; 69(4):2223-9. PubMed ID: 11254577
[TBL] [Abstract][Full Text] [Related]
14. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
15. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Lang AB; Schaad UB; Rüdeberg A; Wedgwood J; Que JU; Fürer E; Cryz SJ
J Pediatr; 1995 Nov; 127(5):711-7. PubMed ID: 7472821
[TBL] [Abstract][Full Text] [Related]
16. Cross-protection by Pseudomonas aeruginosa polysaccharides.
Pier GB
Infect Immun; 1982 Dec; 38(3):1117-22. PubMed ID: 6185423
[TBL] [Abstract][Full Text] [Related]
17. Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.
Pier GB; Bennett SE
J Clin Invest; 1986 Feb; 77(2):491-5. PubMed ID: 3080477
[TBL] [Abstract][Full Text] [Related]
18. Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate).
Hatano K; Goldberg JB; Pier GB
Infect Immun; 1995 Jan; 63(1):21-6. PubMed ID: 7528730
[TBL] [Abstract][Full Text] [Related]
19. Isolation and characterization of a human monoclonal antibody that recognizes epitopes shared by Pseudomonas aeruginosa immunotype 1, 3, 4, and 6 lipopolysaccharides.
Lang AB; Fürer E; Larrick JW; Cryz SJ
Infect Immun; 1989 Dec; 57(12):3851-5. PubMed ID: 2509371
[TBL] [Abstract][Full Text] [Related]
20. [Protective artificial polysaccharide-protein antigens made from the O-specific polysaccharides of Pseudomonas aeruginosa bacteria of the immunotypes 1, 2 and 7].
Kul'shin VA; Antsiferova NG; Moroz AF; Dmitriev BA
Zh Mikrobiol Epidemiol Immunobiol; 1988 Nov; (11):69-71. PubMed ID: 2464262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
